These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Tanner J; Weis J; Fearon D; Whang Y; Kieff E Cell; 1987 Jul; 50(2):203-13. PubMed ID: 3036369 [TBL] [Abstract][Full Text] [Related]
30. Establishment and characterization of Epstein-Barr virus gp350-expressing transfected human lymphoid (Raji) cell clones. Khyatti M; Patel PC; Menezes J Int J Cancer; 1991 Jun; 48(4):591-7. PubMed ID: 1646179 [TBL] [Abstract][Full Text] [Related]
31. Structure of the Epstein-Barr virus oncogene BARF1. Tarbouriech N; Ruggiero F; de Turenne-Tessier M; Ooka T; Burmeister WP J Mol Biol; 2006 Jun; 359(3):667-78. PubMed ID: 16647084 [TBL] [Abstract][Full Text] [Related]
32. CD21 (Complement Receptor 2) Is the Receptor for Epstein-Barr Virus Entry into T Cells. Smith NA; Coleman CB; Gewurz BE; Rochford R J Virol; 2020 May; 94(11):. PubMed ID: 32238579 [TBL] [Abstract][Full Text] [Related]
33. Extended flexible linker structures in the complement chimaeric conjugate CR2-Ig by scattering, analytical ultracentrifugation and constrained modelling: implications for function and therapy. Gilbert HE; Aslam M; Guthridge JM; Holers VM; Perkins SJ J Mol Biol; 2006 Feb; 356(2):397-412. PubMed ID: 16375923 [TBL] [Abstract][Full Text] [Related]
34. Identification of three gp350/220 regions involved in Epstein-Barr virus invasion of host cells. Urquiza M; Lopez R; Patiño H; Rosas JE; Patarroyo ME J Biol Chem; 2005 Oct; 280(42):35598-605. PubMed ID: 16087675 [TBL] [Abstract][Full Text] [Related]
35. Identification of multiple potent neutralizing and non-neutralizing antibodies against Epstein-Barr virus gp350 protein with potential for clinical application and as reagents for mapping immunodominant epitopes. Mutsvunguma LZ; Rodriguez E; Escalante GM; Muniraju M; Williams JC; Warden C; Qin H; Wang J; Wu X; Barasa A; Mulama DH; Mwangi W; Ogembo JG Virology; 2019 Oct; 536():1-15. PubMed ID: 31377598 [TBL] [Abstract][Full Text] [Related]
36. The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21). Hannan JP Curr Protein Pept Sci; 2016; 17(5):463-87. PubMed ID: 26916158 [TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity. Khyatti M; Patel PC; Stefanescu I; Menezes J J Virol; 1991 Feb; 65(2):996-1001. PubMed ID: 1846213 [TBL] [Abstract][Full Text] [Related]
38. A B-lymphocyte binding peptide from BNRF1 induced antibodies inhibiting EBV-invasion of B-lymphocytes. López R; Urquiza M; Patino H; Suárez J; Reyes C; Patarroyo MA; Patarroyo ME Biochimie; 2005 Nov; 87(11):985-92. PubMed ID: 15927339 [TBL] [Abstract][Full Text] [Related]
39. Cloning and analysis of the Epstein-Barr virus glycoprotein 350 genes. Chang SH; Kim SH; Lee WK; Kim HJ; Choi SH; Park JH; Jang HS; Chung GH; Kwon TH; Kim DH; Yang MS; Jang YS Mol Cells; 1998 Oct; 8(5):585-93. PubMed ID: 9856346 [TBL] [Abstract][Full Text] [Related]
40. Solution structure of the complex between CR2 SCR 1-2 and C3d of human complement: an X-ray scattering and sedimentation modelling study. Gilbert HE; Eaton JT; Hannan JP; Holers VM; Perkins SJ J Mol Biol; 2005 Feb; 346(3):859-73. PubMed ID: 15713468 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]